Search for dissertations about: "123I-FP-Cit"

Found 3 swedish dissertations containing the word 123I-FP-Cit.

  2. 1. Nuclear medicine methods in idiopathic Parkinsonism : pre- and postsynaptic dopamine SPECT

    Author : Susanna Jakobson Mo; Katrine Åhlström Riklund; Anne Larsson Strömvall; Lars Forsgren; Rimma Axelsson; Umeå universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Nuclear medicine; SPECT; 123I-FP-Cit; 123I-IBZM; dopamine; parkinsonism; Parkinson’s disease; multiple system atrophy; progressive supranuclear palsy; Radiology; radiologi;

    Abstract : Background: Single photon emission computed tomography (SPECT) with dopamine transporter (DAT) and dopamine D2 receptor (D2R) ligands can visualise the integrity of the nigrostriatal dopamine system. Parkinson’s disease (PD) and the atypical parkinsonian diseases (APD), progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), have similar symptoms and dopamine depletion, but differ in pharmacological response and prognosis. READ MORE

  4. 2. Towards Clinical Implementation of Dynamic Positron Emission Tomography in Neurodegenerative Diseases

    Author : My Jonasson; Mark Lubberink; Lieuwe Appel; Jens Sörensen; Michel Koole; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Positron emission tomography; PET; Molecular imaging; Quantification; Kinetic modelling; Parametric images; Alzheimer’s disease; Parkinson’s disease; Radiology; Radiologi;

    Abstract : Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative disorders worldwide. Positron emission tomography (PET), together with suitable biomarkers, can aid in the clin-ical evaluation as well as in research investigations of these diseases. READ MORE

  5. 3. Validation of a novel PET imaging marker for dopaminergic degeneration in Parkinson’s disease patients

    Author : Vera S Kerstens; Karolinska Institutet; Karolinska Institutet; []
    Keywords : ;

    Abstract : Background: There is a need for an objective disease progression marker for Parkinson’s disease (PD). DAT measurement with PET-radioligand [18F]FE-PE2I has so far shown to be promising with its favorable kinetics, low production of metabolites, and ability to image the whole nigrostriatal pathway. READ MORE